del Campo JM, et al. – In this study, researchers examined the clinical benefit and patient-reported outcomes in patients who had a partial response (PR) and complete response (CR) to their last platinum-based therapy. The study sample consisted of 553 patients with recurrent ovarian cancer. In patients treated with niraparib vs placebo, progression-free survival was improved, and the incidence of any-grade and grade ≥ 3 adverse events was manageable. The investigators did not observe any meaningful differences between treatments in the PR and CR subgroups with respect to patient-reported outcomes. Overall, patients who received niraparib maintenance treatment achieved clinical benefit irrespective of response to the last platinum-based therapy.